Abstract: An antibody conjugating peptide including an amino acid having a photoreactive functional group, a physiologically active substance modified with the conjugating peptide, and an antibody conjugate having an antibody linked to the physiologically active substance are disclosed. When the physiologically active substance modified with the conjugating peptide is linked to the antibody, the conjugation efficiency between the antibody and the physiologically active substance is remarkably improved as compared to that of the conventional art, and thus, the drug may be firmly bound without impairing the specificity of the antibody, thereby making it possible to accelerate commercialization of the antibody conjugate.

Abstract: The present invention relates to an antibody conjugating peptide including an amino acid having a photoreactive functional group, a physiologically active substance modified with the conjugating peptide, and an antibody conjugate having an antibody linked to the physiologically active substance. When the physiologically active substance modified with the conjugating peptide according to the present invention is linked to the antibody, the conjugation efficiency between the antibody and the physiologically active substance is remarkably improved as compared to that of the conventional art, and thus, the drug may be firmly bound without impairing the specificity of the antibody, thereby making it possible to accelerate commercialization of the antibody conjugate.

Abstract: The present invention relates to an antibody conjugating peptide including an amino acid having a photoreactive functional group, a physiologically active substance modified with the conjugating peptide, and an antibody conjugate having an antibody linked to the physiologically active substance. When the physiologically active substance modified with the conjugating peptide according to the present invention is linked to the antibody, the conjugation efficiency between the antibody and the physiologically active substance is remarkably improved as compared to that of the conventional art, and thus, the drug may be firmly bound without impairing the specificity of the antibody, thereby making it possible to accelerate commercialization of the antibody conjugate.

Abstract: A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided.

Abstract: An exercise apparatus may include a swivel and one or more elongated members, such as ropes or cords, suspended from the swivel with a support, such as a bar, for the user suspended between either ends of a single elongated member, or between two elongated members. The height of the support can be adjusted by placing ends of the support bar in loops formed along the elongated member. Hand holds and foot holds may also be mounted on the loops. In addition, the support may be prevented from rotating along its longitudinal axis.

Abstract: An exercise apparatus may include a swivel and one or more elongated members, such as ropes or cords, suspended from the swivel with a support, such as a bar, for the user suspended between either ends of a single elongated member, or between two elongated members. The height of the support can be adjusted by placing ends of the support bar in loops formed along the elongated member. Hand holds and foot holds may also be mounted on the loops. In addition, the support may be prevented from rotating along its longitudinal axis.